Prevention of nausea and vomiting associated with chemotherapy

Active Ingredient: Fosaprepitant

Indication for Fosaprepitant

Population group: only adults (18 years old or older)
Therapeutic intent: Preventive action

Prevention of nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in adults.

For this indication, competent medicine agencies globally authorize below treatments:

150 mg

Route of admnistration

Intravenous

Defined daily dose

150 - 150 mg

Dosage regimen

From 150 To 150 mg once every day

Detailed description

The recommended dose is 150 mg administered as an infusion over 20-30 minutes on Day 1, initiated approximately 30 minutes prior to chemotherapy. Fosaprepitant should be administered in conjunction with a corticosteroid and a 5-HT3 antagonist as specified in the tables below.

The following regimens are recommended for the prevention of nausea and vomiting associated with emetogenic cancer chemotherapy.

Table 1. Recommended dosing for the prevention of nausea and vomiting associated with highly emetogenic chemotherapy regimen in adults:

 Day 1Day 2Day 3Day 4
Fosaprepitant150 mg intravenouslynonenonenone
Dexamethasone12 mg orally8 mg orally8 mg orally twice daily8 mg orally twice daily
5-HT3 antagonistsStandard dose of 5-HT3 antagonists. See the product information for the selected 5-HT3 antagonist for appropriate dosing informationnonenonenone

Dexamethasone should be administered 30 minutes prior to chemotherapy treatment on Day 1 and in the morning on Days 2 to 4. Dexamethasone should also be administered in the evenings on Days 3 and 4. The dose of dexamethasone accounts for active substance interactions.

Table 2. Recommended dosing for the prevention of nausea and vomiting associated with moderately emetogenic chemotherapy regimen in adults:

 Day 1
Fosaprepitant150 mg intravenously
Dexamethasone12 mg orally
5-HT3 antagonistsStandard dose of 5-HT3 antagonists. See the product information for the selected 5-HT3 antagonist for appropriate dosing information

Dexamethasone should be administered 30 minutes prior to chemotherapy treatment on Day 1. The dose of dexamethasone accounts for active substance interactions.

Dosage considerations

It should be administered as an infusion over 20-30 minutes.

Active ingredient

Fosaprepitant

Fosaprepitant is the prodrug of aprepitant and when administered intravenously is converted rapidly to aprepitant. The contribution of fosaprepitant to the overall antiemetic effect has not fully been characterised, but a transient contribution during the initial phase cannot be ruled out.

Read more about Fosaprepitant

Related medicines

Develop a tailored medication plan for your case, considering factors such as age, gender, and health history

Ask the Reasoner

Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.